Key facts
- It has raised $15.3M; the latest was Early Stage VC ($13.9M) in Aug 2025.
- Notable investors include Dalton Venture, Hangzhou Oufang Venture Capital Management, Roton Capital, Silicon Valley Real Stone Asset Management, Xinghua Dingli Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Weiyuan Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Weiyuan Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Weiyuan Biotechnology
Provider of enzyme evolution and high-throughput screening technologies intended to enhance the production of chiral compounds, active natural product extraction and rapid construction of recombinant cell factories. The company's biotechnologies are based on the intelligent evolution of enzymes and high-throughput screening of strains, as well as precision analysis and intelligent prediction techniques, providing businesses in the biotechnology sector with improved production of chiral compounds, increased efficiency in the extraction of active natural products and faster construction of recombinant cell factories.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2023
- Website
- wybio.cc/
- Ownership
- Privately Held (backing)
Weiyuan Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Weiyuan Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Weiyuan Biotechnology in its N-PORT filings yet. We sweep new filings monthly.